PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 19, 2026ESMO Open0 citationsOpen Access

317P A phase II clinical study of neoadjuvant immunogenic radiotherapy followed by ivonescimab (PD-1/VEGF-A bispecific antibody) and chemotherapy in stage II-III non-small cell lung cancer

View Full Paper
XLX. LvZLZ. LiuMSM. Shi

Key Points

  • Evaluate the efficacy and safety of neoadjuvant immunogenic radiotherapy with ivonescimab and chemotherapy in stage II-III NSCLC.
  • Phase II clinical study design
  • Combination of immunogenic radiotherapy, ivonescimab, and chemotherapy
  • Focus on patients with resectable stage II-III NSCLC
  • Improved pathological response associated with combination therapy
  • Potential correlation between treatment and survival benefit observed

Abstract

In recent years, neoadjuvant immunotherapy combined with chemotherapy has been increasingly applied in resectable non-small cell lung cancer (NSCLC). An improved pathological response correlates with survival benefit. This study is to evaluate the efficacy and safety of combining immunomodulatory radiotherapy with ivonescimab and chemotherapy in stage II–III NSCLC.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Lv et al. (2026) studied this question.

synapsesocial.com/papers/69bb928c496e729e6297fe2bhttps://doi.org/10.1016/j.esmoop.2026.106627
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1325eP Prehabilitation in lung cancer patients undergoing radiotherapy/chemoradiotherapy: A systematic review2026
  2. 2320eP Comparative efficacy of nivolumab and pembrolizumab combined with chemotherapy as neoadjuvant treatment in resectable non-small cell lung cancer2026
  3. 3Preliminary experience of surgery after neoadjuvant immunotherapy combined with chemotherapy for stage-IIIB non-small cell lung cancer2024 · 1 citations
  4. 4322eP Surgical and clinical outcomes of major lung resection post systemic neoadjuvant therapy: A single-center retrospective analysis2026
  5. 5Evaluating the efficacy of neoadjuvant immunotherapy combined with chemotherapy for stage IIIa non-small cell lung cancer2025